COLLEGE

TER BEOORDELING VAN

c B G

M E B

EVALUATION

BOARD

$$\frac{c \ B \ G}{M \ E \ B}$$

CBG – MEB: National and European developments

Aginus A.W. Kalis

$$\frac{\text{C} \quad \text{B} \quad \text{G}}{M \quad E \quad B}$$

Topics

- Introduction
- The choices of a national Competent Authority anno 2006
- Developments in Europe
- Developments in the Netherlands
- Conclusion

$$\frac{\text{c} \quad \text{B} \quad \text{G}}{M \quad E \quad B}$$

Introduction

- MEB in the middle of changes (I apologize for being egocentric)
- European legislation just renewed
- New Dutch legislation will be implemented
- European network of regulatory agencies in evolution

$$\frac{\text{C} \quad \text{B} \quad \text{G}}{M \quad E \quad B}$$

The choices of a National Competent Authority anno 2006

- Review 2001 and EMeA Road Map to 2010: EU network of National and European Competent Authorities
- Every Member State chooses his level of responsibility, with respect to:
 - Functioning as rapporteur in CP
 - Acting as RMS in DCP and MRP
 - Taking the lead in European discussions

$$\frac{c \ B \ G}{M \ E \ B}$$

Developments in Europe

- Further Improvement of the procedures:
 - Faster access to innovative medicinal products
 - Better knowledge / science base for authorised medicinal products
 - Harmonization
- Strengthening of pharmacovigilance:
 - Risk Management Plans
 - -Work sharing
 - Better knowledge science based
 - -ICT: Electronic Medication Dossier

$$\frac{c \ B \ G}{M \ E \ B}$$

Developments in Europe (2)

- From GxP for pharmaceutical industry to Good Regulatory Practices in competent authorities:
 - Development of Quality thinking
 - European Benchmark
- Strengthening of transparency
 - Accountability
 - Make better use of existing knowledge about medicinal products
 - "New" stake holders: patients and health care professionals

$$\frac{\text{C} \quad \text{B} \quad \text{G}}{M \quad E \quad B}$$

Developments in the Netherlands

- 2004 2005: business plan developed
- Main objective defined:
 - Maintain position in Top 5 of Europe:
 - Choice of special-interest areas
 - Maintain quality of work
 - Strengthening of Pharmacovigilance
 - ISO-certification
 - Establish a transparent organisation

$$\frac{c \ B \ G}{M \ E \ B}$$

Developments in the Netherlands (2)

- 2005: Pharmacovigilance department reestablished.
- 2005: Veterinary Department
- 2005: Novel Foods Unit
- 2006: Covenants with academia and university hospitals
 - Topics: special interest areas, pharmaco-epidemiology
- 2006: ISO 9001:2000, quality assurance system

$$\frac{c \ B \ G}{M \ E \ B}$$

Developments in the Netherlands (3)

- Future (2007): Organizational changes:
 - New IT system ICI
 - Paperless environment, electronic submissions
 - Workflow Management
 - Moving to a new office building
- Strengthening national collaboration between competent authorities

$$\frac{c \ B \ G}{M \ E \ B}$$

Conclusions

- Networking organisation
- Challenging times
- Ongoing reorganization
- Ongoing improvement

For a golden future of the European Regulatory System and for Public Health!

COLLEGE

TER BEOORDELING VAN

GENEESMIDDELEN

 $\frac{C}{M} = \frac{B}{B}$

MEDICINES EVALUATION BOARD